Key Highlights
- Coherus Oncology shares are up 6.50% in pre-market trading to $1.22, following a 4.17% decline to $1.15 at Monday's close.
- The company announced a Special Dividend of contingent value rights (CVRs), entitling stockholders of record as of September 30, 2026 to a pro rata share of net proceeds from the planned sale of its remaining legacy biosimilar assets.
- The move completes Coherus' transformation into a fully integrated, innovative immuno-oncology company, following its 2025 rebrand from Coherus BioSciences.
- The Legacy BioSim Assets being monetized include patents, intellectual property, royalties, cell lines, and related regulatory materials, with the CVRs set to expire on October 7, 2028 if no proceeds are received.
What's Driving the Gain
Coherus Oncology (NASDAQ:CHRS) shares are trading higher in pre-market activity after the company announced a special dividend tied to the planned divestiture of its remaining biosimilar business. Coherus is a Redwood City, California-based, fully integrated commercial-stage oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), and a pipeline of mid-stage clinical candidates targeting liver, head and neck, colorectal, and other gastrointestinal cancers.
The company announced a special dividend of contingent value rights, or CVRs, which will be distributed on a pro rata basis to stockholders of record as of September 30, 2026, with a distribution date of October 7, 2026. The CVRs entitle holders to receive their pro rata share of any future net cash proceeds from the sale or monetization of the company's remaining Legacy BioSim Assets, which include patents, intellectual property, royalties under an existing license agreement, cell lines, and related regulatory materials. CEO Denny Lanfear said the move completes the company's transformation into a focused, innovative oncology company, and that Coherus has retained an Investment bank to run the sale process.
What the CVRs Mean for Shareholders
The CVRs will not be certificated, will not represent Equity or ownership interests in the company, will not bear interest, and will not be listed on any securities exchange or have a public trading market. They are non-transferrable and will expire on October 7, 2028, the second anniversary of the distribution date; if no net proceeds are received from the sale of the legacy assets before that date, the CVRs will expire without payment. Coherus' common stock will remain outstanding, listed, and freely tradable following the distribution. The company's broader immuno-oncology pipeline includes casdozokitug, an IL-27 antagonistic antibody in a randomized Phase 2 study for liver cancer, and tagmokitug, a cytolytic anti-CCR8 antibody in Phase 1b/2a studies across several solid tumor types.
Conclusion
Coherus Oncology shares are higher in pre-market trading as investors respond positively to the company's plan to monetize its legacy biosimilar assets and sharpen its focus on immuno-oncology. With a defined Record Date and distribution timeline now in place for the CVR dividend, investors will likely be watching for updates on the biosimilar asset sale process in the coming months.






Please wait processing your request...